Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
Recent studies have shown that GLP-1R agonists can significantly improve hepatic fat content and liver function indexes in patients with MASLD, thereby reducing the risk of progression to Chronic Liver Disease in patients with MASLD (Singh et al., 2024
Without a pre-treatment A1c, that improvement is invisible
Instead of following Sanofi, it led with a list price increase in order to set a high basal insulin price floor from which to launch Tresibas initial list price
"Oral SLU-PP-332" marketed with claims of "high oral bioavailability" that contradicts Billon 2025 (PMID 41421047), which is the paper that explicitly identified the parent compound's lack of oral bioavailability as the reason SLU-PP-915 was developed
US$ 23.85
US$ 20.71
US$ 25.16
